Evidence map›Paper›PMID 42101175›Full record

ArticleMolecular nutrition & food research2026

High-Density Lipoprotein-Specific Phospholipid Efflux (HDL-SPE) Assay in Mice.

Masaki Sato, Edward B Neufeld, Masato Hamasaki, Alan T Remaley, Kazuhiko Kotani

Abstract readLetter
In one paragraph

Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masaki SatoDivision of Community and Family Medicine and Department of Clinical Laboratory Medicine, Jichi Medical University, Shimotsuke-City, Tochigi, Japan.ORCID 0000-0003-1277-7645
Edward B NeufeldLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Masato HamasakiDivision of Community and Family Medicine and Department of Clinical Laboratory Medicine, Jichi Medical University, Shimotsuke-City, Tochigi, Japan.
Alan T RemaleyLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kazuhiko KotaniDivision of Community and Family Medicine and Department of Clinical Laboratory Medicine, Jichi Medical University, Shimotsuke-City, Tochigi, Japan.ORCID 0000-0001-8119-633X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent study by Martínez-Beamonte et al. provides new insights into how extra virgin olive oil enriched in bioactive compounds may exert anti-atherogenic effects, by improving high-density lipoprotein (HDL) function, as determined by the high-density lipoprotein-specific phospholipid efflux (HDL-SPE) assay in Apoe-deficient mice. We would like to highlight two points. First, the HDL-SPE assay was validated in human samples, but there is only limited data on how it performs in mice. Second, the role of ApoE in ApoA-I-containing HDL may differ substantially between mice and humans. The finding by Martínez-Beamonte et al. is quite intriguing, but it will be important to extend their findings in mice to human subjects.

Indexed as

Lipoproteins, HDLPhospholipidsAnimalsApolipoprotein A-IApolipoproteins EAtherosclerosisHumansMiceOlive OilPlant OilsApolipoprotein A-IApolipoproteins ELipoproteins, HDLOlive OilPhospholipidsPlant Oils

Identifiers

PMID42101175
PMCPMC13155053

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.